Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2010 - 2026)

Rigel Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 8654000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 24.39% year-over-year to 8654000.0; the TTM figure through Mar 2026 stood at 364232000.0 (up 879.7% YoY), while the FY2025 annual figure was 367024000.0, up 1999.08% from the prior year.
• Income from Continuing Operations was 8654000.0 for Q1 2026 at Rigel Pharmaceuticals, down from 268065000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 268065000.0 in Q4 2025 to a low of 27445000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 18205823.53 across 5 years, with a median of 737000.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slumped 169.48% in 2022, then soared 5887.67% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 1401000.0 in 2022, then slumped by 47.39% to 737000.0 in 2023, then soared by 1845.86% to 14341000.0 in 2024, then surged by 1769.22% to 268065000.0 in 2025, then slumped by 96.77% to 8654000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 8654000.0 (Q1 2026), 268065000.0 (Q4 2025), and 27900000.0 (Q3 2025), per Business Quant data.